Results from a carotid intima-media thickness trial as a decision tool for launching a large-scale morbidity and mortality trial

Circulation: Cardiovascular Imaging

Volumn 6, Issue 1, 2013, Pages 20-25

  Peters, Sanne A E ^a   Den Ruijter, Hester M ^a   Grobbee, Diederick E ^a   Bots, Michiel L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Atherosclerosis; Carotid intima media thickness; Epidemiology; Noninvasive imaging; Trials

Indexed keywords

ATENOLOL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; LOSARTAN; NICOTINIC ACID; PLACEBO; RAMIPRIL; TORCETRAPIB;

ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; DRUG EFFICACY; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); MORBIDITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; ATHEROSCLEROSIS; CAROTID ARTERY; DECISION MAKING; DISEASE COURSE; ECHOGRAPHY; HEALTH; METHODOLOGY; REVIEW; SURVIVAL RATE;

ATHEROSCLEROSIS; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; DECISION MAKING; DISEASE PROGRESSION; HUMANS; MORBIDITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; WORLD HEALTH;

MLCS; MLOWN;

EID: 84874524699     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.112.978114     Document Type: Article

References (37)

1. World Health Organization. The World Health Report 2008. http://www.who.int/whr/2008/en/index.html. Accessed June 7, 2012.
2. Libby P, Ridker PM, Maseri A. Infammation and atherosclerosis. Circulation. 2002;105:1135-1143.
3. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31-40.
4. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiologi-cal studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557-567.
5. Peters SA, Grobbee DE, Bots ML. Carotid intima-media thickness: a suitable alternative for cardiovascular risk as outcome? Eur J Cardiovasc Prev Rehabil. 2011;18:167-174.
6. Peters SA, den Ruijter HM, Bots ML. Attenuation of rate of change in carotid intima-media thickness by lipid-modifying drugs: impact on clinical outcomes. Am J Cardiovasc Drugs. 2011;11:253-263.
7. Costanzo P, Perrone-Filardi P, Vassallo E, Paolillo S, Cesarano P, Brevetti G, et al. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. J Am Coll Cardiol. 2010;56:2006-2020.
8. Goldberger ZD, Valle JA, Dandekar VK, Chan PS, Ko DT, Nallamothu BK. Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis. Am Heart J. 2010;160:701-714.
9. Taylor AJ, Bots ML, Kastelein JJ. Vascular disease: meta-regression of CIMT trials-data in, garbage out. Nat Rev Cardiol. 2011;8:128-130.
10. Espeland MA, O'leary DH, Terry JG, Morgan T, Evans G, Mudra H. Carotid intima-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med. 2005;6:3.
11. Taylor F, Ward K, Moore TH, Burke M, Davey SG, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;CD004816.
12. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Effcacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371: 117-125.
13. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, et al. Safety and effcacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378:1547-1559.
14. Lüscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Münzel T, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33:857-865.
15. Tropeano AI, Saleh N, Hawajri N, Macquin-Mavier I, Maison P. Do all antihypertensive drugs improve carotid intima-media thickness? A network meta-analysis of randomized controlled trials. Fundam Clin Pharmacol. 2011;25:395-404.
16. Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006;37:1933-1940.
17. Zanchetti A. The antiatherogenic effects of antihypertensive treatment: trials completed and ongoing. Curr Hypertens Rep. 2001;3:350-359.
18. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
19. Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012;64:285-296.
20. Suurküla M, Agewall S, Fagerberg B, Wendelhag I, Wikstrand J. Multiple risk intervention in high-risk hypertensive patients. A 3-year ultrasound study of intima-media thickness and plaques in the carotid artery. Risk Intervention Study (RIS) Group. Arterioscler Thromb Vasc Biol. 1996;16:462-470.
21. Peters SA, den Ruijter HM, Bots ML. Ultrasound protocols to measure carotid intima-media thickness: one size does not ft all. J Am Soc Echo-cardiogr. 2012;25:1135-1137.
22. Peters SA, den Ruijter HM, Palmer MK, Grobbee DE, Crouse JR III, O'Leary DH, et al. Biologically implausible carotid intima-media thickness measurement values: effects on rate of change over time. Curr Med Res Opin. 2012;28:891-899.
23. Peters SA, Bots ML, den Ruijter HM, Palmer MK, Grobbee DE, Crouse JR III, et al. Multiple imputation of missing repeated outcome measurements did not add to linear mixed-effects models. J Clin Epidemiol. 2012;65:686-695.
24. Peters SA, Palmer MK, den Ruijter HM, Grobbee DE, Crouse JR III, O'Leary DH, et al. Sample size requirements in trials using repeated measurements and the impact of trial design. Curr Med Res Opin. 2012;28:681-688.
25. Peters SA, den Ruijter HM, Palmer MK, Grobbee DE, Crouse JR III, O'Leary DH, et al. Extensive or restricted ultrasound protocols to measure carotid intima-media thickness: analysis of completeness rates and impact on observed rates of change over time. J Am Soc Echocardiogr. 2012;25:91-100.
26. Peters SA, den Ruijter HM, Palmer MK, Grobbee DE, Crouse JR III, O'Leary DH, et al. Manual or semi-automated edge detection of the maximal far wall common carotid intima-media thickness: a direct comparison. J Intern Med. 2012;271:247-256.
27. Peters SA, Palmer MK, Grobbee DE, Crouse JR III, Evans GW, Raichlen JS, et al. Effect of number of ultrasound examinations on the assessment of carotid intima-media thickness changes over time: the example of the METEOR study. J Hypertens. 2011;29:1145-1154.
28. Dogan S, Plantinga Y, Evans GW, Meijer R, Grobbee DE, Bots ML, et al. Ultrasound protocols to measure carotid intima-media thickness: a post-hoc analysis of the OPAL study. Curr Med Res Opin. 2009;25:109-122.
29. Dogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. J Athero-scler Thromb. 2010;17:526-535.
30. Dogan S, Plantinga Y, Crouse JR III, Evans GW, Raichlen JS, O'Leary DH, et al. Algorithms to measure carotid intima-media thickness in trials: a comparison of reproducibility, rate of progression and treatment effect. J Hypertens. 2011;29:2181-2193.
31. Dogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, et al. Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Ann Med. 2010;42:447-464.
32. Dogan S, Kastelein JJ, Grobbee DE, Bots ML. Mean common or mean maximum carotid intima-media thickness as primary outcome in lipid-modifying intervention studies. J Atheroscler Thromb. 2011;18:946-957.
33. Espeland MA, Craven TE, Riley WA, Corson J, Romont A, Furberg CD. Reliability of longitudinal ultrasonographic measurements of carotid inti-mal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke. 1996;27:480-485.
34. Espeland MA, Craven TE, Miller ME, D'Agostino R Jr. 1996 Remington lecture: modeling multivariate longitudinal data that are incomplete. Ann Epidemiol. 1999;9:196-205.
35. Polak JF, Pencina MJ. Measuring carotid artery intima-media thickness: simplicity versus complexity? J Am Soc Echocardiogr. 2012;25:101-104.
36. Polak JF, Pencina MJ, Herrington D, O'Leary DH. Associations of edge-detected and manual-traced common carotid intima-media thickness measurements with Framingham risk factors: the multi-ethnic study of atherosclerosis. Stroke. 2011;42:1912-1916.
37. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21:93-111; quiz 189.